This move is archived. Current quotes and coverage live on the stock page.
Follow CRDL
Cardiol Therapeutics Inc Class A has seen a notable decline in its stock price, raising concerns among investors.
In today's trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) is down by 3.72%. This drop comes amid a tough market for many biotech firms.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$161.61M
52W high
$3.23
52W low
$1.23
1W change
-14.29%
Beta
0.66
Analyst Price Targets
Based on analyst covering CRDL · as of Oct 12, 2026
Wall Street analysts forecast CRDL stock price to rise 655.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.00
+655.5% Upside
Previously C$6.00 on Sep 17, 2026
Current Price
C$0.93
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
55.0%
Annualized
90-Day Vol
70.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.25 | C$1.04 – C$1.51 |
| 60 trading days | C$1.18 | C$0.90 – C$1.54 |
| 90 trading days | C$1.11 | C$0.80 – C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep a close eye on Cardiol Therapeutics' performance and any upcoming announcements that could affect its stock price.
Stock down 3.72% today
Cardiol Therapeutics Inc Class A's market cap now stands at about CA$244 million following today's decline.
Bull case
Despite the current downturn, Cardiol Therapeutics has shown promise in its clinical trials and operational updates, which could set the stage for future growth.
Bear case
The recent drop in stock price might suggest underlying issues or market skepticism about the company's ability to meet expectations, especially in a competitive biotech landscape.
Current Market Performance
Currently, Cardiol Therapeutics' stock is trading at CA$2.33, reflecting a significant drop in value. This decline is concerning for investors who are closely monitoring the company's developments and market position.
Potential Factors Behind the Decline
While there hasn't been any specific news from the company today, the biotech sector often experiences volatility due to regulatory challenges and market sentiment. Investors should consider how these factors might be affecting Cardiol Therapeutics' stock performance. For more insights on the company's financials, check out our detailed analysis on Cardiol Therapeutics Inc Class A.
Looking Ahead
Investors should stay alert for any announcements from Cardiol Therapeutics that could impact its stock price. The company's ongoing clinical trials and operational updates will be key in determining its future performance. For further information on Cardiol's market position, visit our CRDL.TO page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
